Molbio Diagnostics shares jump 5% as HDFC MF buys 1.99% stake via bulk deal
60-Word AI Digest
Molbio Diagnostics shares rose over 5% on October 1, after HDFC Mutual Fund acquired a 1.99% stake. The stock gained approximately 71% since its IPO, and Jefferies assigned a ‘Buy’ rating, setting a target price of ₹1,600, indicating over 98% upside potential.
Key Takeaways
- Molbio Diagnostics shares rose over 5% on October 1, after HDFC Mutual Fund acquired a 1.99% stake.
- The stock gained approximately 71% since its IPO, and Jefferies assigned a ‘Buy’ rating, setting a target price of ₹1,600, indicating over 98% upside potential.
- Full details and original dispatch available below.
Molbio Diagnostics shares rose over 5% on October 1, after HDFC Mutual Fund acquired a 1.99% stake. The stock gained approximately 71% since its IPO, and Jefferies assigned a ‘Buy’ rating, setting a target price of ₹1,600, indicating over 98% upside potential.
Original Publisher Attribution
This summary was curated from Newly listed stock up 71% from IPO price.